SHADOW: Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05090982
Collaborator
(none)
150
1
11
13.6

Study Details

Study Description

Brief Summary

Hypothesis/Objective : Patient-centered health care and shared decision making are key components of increasing importance which are recommended by the French Haute Autorite de Sante (HAS) and World Health Organization (WHO).

In the context of dermatology and atopic dermatitis, European guidelines has promoted an active involvement from both patients and caregivers in therapeutic decisions at all stages to achieve therapeutic success and the Task Force on Atopic Dermatitis (ETFAD) has promoted the setting of treatment goals in a shared decision with the patient.

The main objective of this study is to develop and cross culturally validate a tool dedicated to shared-decision in atopic dermatitis that can be used during routine dermatological consultations.

The second objective is to better characterize patients seen in this context and to evaluate patients' satisfaction when empowered by shared decision.

Method : We aim to develop a SDMt in AD following the recommendations of the International Patient Decision Aid Standards (IPDAS) collaboration. Development will use a multistep approach: 1) identification of priority domains for patients; 2) Selection of domains to be included in the SDMt for AD; and 3) Creation and testing of the SDMt.

Participants will be consecutive adult (>18 years old) patients attending consultation for a AD in medical centres in France (Toulouse, Nantes and Créteil). All participants will provide written consent to participate. The study will be submitted for approbation to the local ethics committees of the University Hospital Centres of Paris and will be conducted according to the Declaration of Helsinki.

Step 1: Identification of priority domains for patients

Step 2: Selection of domains to be included in the SDMt for AD

Step 3: Creation and testing of the SDMt

Condition or Disease Intervention/Treatment Phase
  • Other: Audio recordings during the consultations
  • Other: Audio recordings during the consultations and test of the shared medical decision-making tool for modification
  • Other: Audio recordings during the consultations and test of the shared medical decision-making tool for validation

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Patients with Atopic dermatitis

150 patients with Atopic dermatitis

Other: Audio recordings during the consultations
50 patients with audio recordings of the consultation

Other: Audio recordings during the consultations and test of the shared medical decision-making tool for modification
50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification

Other: Audio recordings during the consultations and test of the shared medical decision-making tool for validation
50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.

Outcome Measures

Primary Outcome Measures

  1. Creation of a shared medical decision-making tool in the context of a consultation for atopic dermatitis in a specialized dermatology consultation. [through study completion, an average of 1 year]

    Qualitative descriptions of the topics discussed by the patient during the therapeutic decision in a specialized dermatology consultation for atopic dermatitis; in other words, to characterize the topics discussed by the patient during the consultation

Secondary Outcome Measures

  1. Patient satisfaction with the therapeutic decision-making process [during the intervention]

    SURE satisfaction score

  2. Assessment of the perceived state of the patient about the intervention [during the intervention]

    Validation tool score CollaboRATE

  3. Assessment of the psychological state of the patient [during the intervention]

    Validation tool score GAD-7

  4. Assessment of the perceived health state of the patient [during the intervention]

    Score of PHQ-9 questionnaire

  5. Assessment of the quality of life of the patient [during the intervention]

    Score of DLQI questionnaire

  6. Assessment of the stigmatization perceived by the patient [during the intervention]

    6-items Stigmatization scale

  7. Assessment of the severity perceived by the patient [during the intervention]

    Atopic Dermatitis Perceived Severity Scale

  8. Description of treatment compliance in patients who received the validated tool [during the intervention]

    Compliance with treatment received

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥18 years, male or female.

  • Patient with atopic dermatitis

  • Written information given to the patient and no objection from the patient to participate to the study

Exclusion Criteria:
  • Patient under guardianship or curatorship

  • Patient with cognitive dysfunction that makes it impossible to communicate effectively or to complete the questionnaire

  • Patient under AME

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Henri Mondor Créteil France 64010

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Study Director: Pierre-André Natella, PhD, Assistance Publique - Hôpitaux Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT05090982
Other Study ID Numbers:
  • APHP211198
  • 2021-A01859-32
First Posted:
Oct 25, 2021
Last Update Posted:
Dec 21, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 21, 2021